The Inscopix miniature microscope platform enables researchers to monitor and manipulate circuit pathophysiology over long periods of time in animal models of diverse neurological and psychiatric disorders. This provides an objective and quantitative measure for investigating disease and therapy induced changes directly in the brain.
Dissect the role of specific cell-types and brain circuits in disease etiology and therapeutic intervention
Derive mechanistic insights into disease progression and therapeutic action
Discover predictive and pathological circuit activity-based biomarkers of brain disorders
Identify promising therapeutic targets from functionally defined cell-types
Conduct in vivo drug screening assays in a high-throughput fashion
|Researchers from Stanford & Pfizer used state-of-the-art brain imaging technology, our miniature microscope-based platform nVista, to peer into a brain region called the striatum in a mouse model of Parkinson’s disease (PD). By monitoring activity in hundreds of neurons simultaneously in the living brain, they observed aberrations in striatal activity patterns that encode voluntary movement. The researchers then tested compounds like L-DOPA, the mainstay PD treatment, and other dopamine agonists that have proven to be less efficacious than L-DOPA in the clinic, and found significant correspondence between a compound's ability to correct the pathological striatal activity patterns and its clinical efficacy.|
There have been growing concerns about the adverse effects of the ambient Zolpidem on cognition and memory. In this collaboration between Johnson & Johnson and Inscopix, scientists tracked large-scale calcium dynamics in the hippocampus (a brain region critical for memory) of Zolpidem-administered mice. They discovered that the majority of the hippocampal neurons decreased their rate of calcium transients upon receiving Zolpidem, a potential explanation for the amnesia observed in humans.
Seizure activity has traditionally been assessed with behavioral monitoring and whole-brain EEG recording. By combining these methods with nVista calcium imaging in mice treated with the proconvulsant kainic acid (KA), Johnson & Johnson and Inscopix scientists discovered aberrant calcium dynamics in hippocampal neurons before the onset of behavioral and EEG signatures of convulsive motor seizures. These activity-based signatures signaling an imminent convulsive seizure open up the possibility for pre-emptive therapeutic intervention to mitigate excitotoxic damage to the hippocampus.
At the DECODE Summit (2016), Dr. Garret Stuber (UNC) shared how circuit-level insights can be applied to the development of highly selective drugs. Dr. Stuber used nVista imaging to hone in on a small subset of BNST GABAergic neurons, defined by their expression of the Nociceptingene. These neurons uniformly exhibited enhanced activity as the mouse transitioned to anxiogenic environments. Through single-cell transcriptomic analysis of this Nociceptin+ subpopulation, Dr. Stuber hopes to identify other uniquely expressed genes, potential targets for cell-type specific pharamacological intervention for anxiety disorders.